viewActinogen Medical Ltd

Actinogen Medical enrols first UK patient in Alzheimer’s therapy trial

The annual cost of managing Alzheimer’s disease is estimated to be US$250B in the U.S.

The patient in UK was enrolled at St. Pancras Clinical Research in London

Actinogen Medical (ASX:ACW) has enrolled its first UK patient into XanADu, its international Phase II efficacy and safety trial of Xanamem therapy in patients with mild Alzheimer’s disease.

Xanamem has been specifically designed to block the excess production of cortisol, the stress hormone, in the areas of the brain most affected by Alzheimer’s disease.

The patient in UK was enrolled at St. Pancras Clinical Research in London. This is the sixteenth patient to be enrolled globally across the eighteen research sites currently open.

Actinogen’s trial will enrol 174 patients at 20 research sites across Australia, the U.S. and the UK.

To-date, over 50 patients have been screened for the study, with at least half expected to progress to enrolment into the trial.

The first XanADu patient will complete the study next month, having reached the end of the 12-week dosing period, and now entering the 4-week follow up phase of the trial.

It is estimated that there are nearly 50 million people with Alzheimer’s disease worldwide, increasing to 131 million by 2050, making it critical to find effective new drugs to treat the disease.

The progress in the development of Xanamem is expected to provide an opportunity for Actinogen to make a profound difference to Alzheimer’s patients and their carers worldwide.

Actinogen ended the June quarter with $3.98 million in cash.

Quick facts: Actinogen Medical Ltd

Price: 0.045 AUD

Market: ASX
Market Cap: $50.37 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Piedmont Lithium secures landmark Section 404 Permit to...

Piedmont Lithium Ltd (ASX:PLL) CEO Keith Phillips tells Proactive the lithium explorer has received the Section 404 Permit under the Clean Water Act from the US Army Corps of Engineers for its lithium project in North Carolina. Phillips says this landmark achievement follows a fair, albeit...

2 days, 5 hours ago

2 min read